Barron’s June 2007 Report: Experts Are Concerned That TriCor May Cause Decline In Kidney Functions
(Posted by Tom Lamb at DrugInjuryWatch.com)
The weekly business newspaper Barron’s reported on June 3, 2007 that some expert cardiologists and nephrologists have raised questions about the safety of TriCor (fenofibrate), a drug from Abbott Laboratories Inc. which is intended to help patients lower their triglycerides, or non-cholesterol fat.
According to a June 3, 2007 Reuters article about this TriCor report:
…some experts say they are concerned that fenofibrate, the generic name of TriCor, may cause decline in kidney functions. Other doctors, the U.S. Food & Drug Administration and Abbott executives say there is no cause for concern, the newspaper said.
There was no immediate comment from Abbott on the Barron’s article.
The report comes as analysts predict sales of [TriCor] will grow by double digits in the next few years and Abbott is planning to reformulate it and combine it with a statin to create a product that takes aim at triglycerides and bad cholesterol.
We expect there will be more discussion about this emerging issue about the safety of TriCor in the weeks to come. As stated in the June 2007 Barron’s report, "questions about TriCor seem destined to grow".
P.S. An earlier Barron’s article, "Trials Ahead for a Drug Maker", last updated on June 2, 2007, provided more detail. In summary, a study by prominent cardiologist Steven Nissen, M.D., published in March 2007 by the Journal of the American Medical Association (JAMA) reported that TriCor causes above-normal increases in a substance called creatinine. Increased creatinine levels usually indicate kidney malfunctions. This earlier Barron’s article covers the difference of opinions among medical professionals, along with the views of FDA and Abbott, about whether TriCor is an unsafe drug. According to this Barron’s article, Dr. Steven Nissen’s current position: "There is concern raised by the finding but it is not definitive." (6/5/07)
Leave a Reply to Becky Cancel reply